Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.42 |
| ▸ | CACNG8 | Q8WXS5 | 5/20 | 0.42 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 5/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434019 | 0.82 | KMT2A (0.40) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL7649298 | 0.81 | ALDH1A1 (0.47) | GRIA1CACNG8CACNG2KMT2AAHR | |
| SCHEMBL5363780 | 0.81 | TDP2 (0.46) | GRIA1CACNG8CACNG2KMT2AAHR | |
| SCHEMBL20106766 | 0.81 | TDP2 (0.46) | GRIA1CACNG8CACNG2AHRPKM | |
| SCHEMBL12157511 | 0.81 | GRIA1 (0.41) | GRIA1CACNG8CACNG2CA9AHR | |
| SCHEMBL6411297 | 0.81 | AHR (0.53) | GRIA1CACNG8CACNG2AHRPDK2 | |
| SCHEMBL5498437 | 0.81 | GRIA1 (0.41) | GRIA1CACNG8CACNG2AHRPDK2 | |
| SCHEMBL5357730 | 0.81 | GRIA1 (0.49) | GRIA1CACNG8CACNG2AHRCMA1 | |
| SCHEMBL18208031 | 0.81 | GRIA1 (0.43) | GRIA1CACNG8CACNG2KMT2AAHR | |
| SCHEMBL20085465 | 0.79 | GRIA1 (0.42) | GRIA1CACNG8CACNG2AHRPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| EP-3532477-B1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-26 | — | — | EP | disclosed |
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | disclosed |
| WO-2018138362-A1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018080916-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018080918-A1 | 3-ARYL-2H-PYRAZOLO[4,3-B]PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018080917-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| EP-2205590-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-06-04 | — | — | EP | disclosed |
| CN-102702068-B | 3-pyrrolo-cyclohexylidene-2-dihydroindolone derivative, and application of 3-pyrrolo-cyclohexylidene-2-dihydroindolone derivative | NANJING YOKO BIOLOG PHARMACEUTICAL RES CO LTD | 2014-05-14 | — | — | CN | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20130029975-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| CN-102702068-A | 3-pyrrolo-cyclohexylidene-2-dihydroindolone derivative, and application of 3-pyrrolo-cyclohexylidene-2-dihydroindolone derivative | JIANGSU SIMCERE PHARM RES CO | 2012-10-03 | — | — | CN | disclosed |
| CN-101389624-B | 3-pyrrolocyclohexylidene-2-indolinone derivative and application thereof | JIANGSU SIMCERE PHARM RES CO | 2012-10-03 | — | — | CN | disclosed |
| EP-2123649-B1 | 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDRO-INDOLINONE DERIVATIVES AND USES THEREOF | JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD (CN) | 2012-02-29 | — | — | EP | disclosed |
| US-8084621-B2 | 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof | Jiangsu Simcere Pharmaceutical R&D Co. Ltd. (CN) | 2011-12-27 | — | — | US | disclosed |
| EP-2386558-A1 | CGRP antagonists | Boehringer Ingelheim International GmbH (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20100160318-A1 | 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof | JIANGSU SIMCERE PHARMACEUTICAL R&D CO., LTD. (CN) | 2010-06-24 | — | — | US | disclosed |
| EP-2123649-A1 | 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDRO-INDOLINONE DERIVATIVES AND USES THEREOF | Jiangsu Simcere Pharmaceutical R&D Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
| CN-101389624-A | 3-pyrrolocyclohexylidene-2-indolinone derivative and application thereof | JIANGSU SIMCERE PHARMACEUTICAL (CN) | 2009-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059954-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | GRIA1 318/4885CACNG8 682/4885CACNG2 746/4885 |
| US-20100160318-A1 | 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof | PTK2B, DMPK, STK25 | GRIA1 3840/4885CACNG8 2933/4885CACNG2 3396/4885 |
| US-20130029975-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | GRIA1 318/4885CACNG8 682/4885CACNG2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.